Nothing Special   »   [go: up one dir, main page]

MX2020010116A - Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). - Google Patents

Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).

Info

Publication number
MX2020010116A
MX2020010116A MX2020010116A MX2020010116A MX2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A
Authority
MX
Mexico
Prior art keywords
macrocyclic compounds
kinases inhibitors
trk kinases
trk
inhibitors
Prior art date
Application number
MX2020010116A
Other languages
English (en)
Inventor
Lijun Yang
Tongshuang Li
Xingdong Zhao
Huajie Zhang
Haohan Tan
Qihong Liu
Yanxin Liu
Weibo Wang
Hongbin Liu
Rui Tan
Bin Liu
Weipeng Zhang
Zongyao Zou
Chengxi He
Yuwei Gao
Shu Lin
Hong Fu
Yunling Wang
Original Assignee
Fochon Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Biosciences Ltd filed Critical Fochon Biosciences Ltd
Publication of MX2020010116A publication Critical patent/MX2020010116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan ciertos inhibidores de TRK, sus composiciones farmacéuticas, y métodos de uso de los mismos.
MX2020010116A 2018-03-28 2019-03-27 Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). MX2020010116A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648999P 2018-03-28 2018-03-28
US201862674755P 2018-05-22 2018-05-22
US201862684535P 2018-06-13 2018-06-13
US201962800496P 2019-02-02 2019-02-02
PCT/CN2019/079909 WO2019184955A1 (en) 2018-03-28 2019-03-27 Macrocyclic compounds as trk kinases inhibitors

Publications (1)

Publication Number Publication Date
MX2020010116A true MX2020010116A (es) 2020-11-06

Family

ID=68060871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010116A MX2020010116A (es) 2018-03-28 2019-03-27 Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).

Country Status (10)

Country Link
US (1) US11555042B2 (es)
EP (1) EP3774812A4 (es)
JP (1) JP2021519297A (es)
KR (1) KR20200141041A (es)
CN (1) CN111971287B (es)
AU (1) AU2019241260B2 (es)
BR (1) BR112020019399A2 (es)
CA (1) CA3093140A1 (es)
MX (1) MX2020010116A (es)
WO (1) WO2019184955A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094143A1 (en) 2017-11-10 2019-05-16 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof
WO2019206069A1 (zh) 2018-04-25 2019-10-31 北京普祺医药科技有限公司 一种二芳基巨环化合物、药物组合物以及其用途
CN113773335A (zh) * 2019-06-21 2021-12-10 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2021244609A1 (zh) * 2020-06-04 2021-12-09 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
WO2021259309A1 (zh) * 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
CN111875620B (zh) * 2020-09-28 2020-12-11 上海美迪西生物医药股份有限公司 吡唑并嘧啶类大环衍生物及其应用
WO2022262671A1 (zh) * 2021-06-15 2022-12-22 中国医药研究开发中心有限公司 杂环大环化合物及其医药用途
CN113582994B (zh) * 2021-09-28 2022-02-11 北京鑫开元医药科技有限公司 具有trk激酶抑制活性的化合物、制备方法、组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3205654T3 (pl) * 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
EP3025261A1 (en) 2013-07-26 2016-06-01 Essilor International (Compagnie Générale D'Optique) Self-service prescription eyewear kiosk
CN104672250B (zh) * 2013-11-29 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
KR102402179B1 (ko) * 2014-01-24 2022-05-25 터닝 포인트 테라퓨틱스, 인크. 단백질 키나제의 조절인자로서의 다이아릴 거대환
KR20170005870A (ko) * 2014-05-23 2017-01-16 에프. 호프만-라 로슈 아게 Jak 억제제인 5-클로로-2-다이플루오로메톡시페닐 피라졸로피리미딘 화합물
EP3226688B1 (en) * 2014-12-05 2020-07-01 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant idh enzymes
MX2017017097A (es) * 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
MX2018000718A (es) * 2015-07-21 2020-01-20 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismos.
AU2016311426B2 (en) * 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN108779117B (zh) * 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
WO2017133663A1 (en) * 2016-02-03 2017-08-10 Shanghai Fochon Pharmaceutical Co., Ltd. Phosphorus containing compounds as protein kinase inhibitors
CA3031100A1 (en) 2016-07-28 2018-02-01 Tp Therapeutics, Inc. Macrocycle kinase inhibitors
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用

Also Published As

Publication number Publication date
EP3774812A4 (en) 2021-12-15
US20210139506A1 (en) 2021-05-13
AU2019241260A1 (en) 2020-10-01
CA3093140A1 (en) 2019-10-03
US11555042B2 (en) 2023-01-17
CN111971287A (zh) 2020-11-20
WO2019184955A1 (en) 2019-10-03
KR20200141041A (ko) 2020-12-17
EP3774812A1 (en) 2021-02-17
BR112020019399A2 (pt) 2021-01-05
CN111971287B (zh) 2023-06-02
RU2020133631A3 (es) 2022-05-04
RU2020133631A (ru) 2022-05-04
JP2021519297A (ja) 2021-08-10
AU2019241260B2 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
ZA201807256B (en) Inhibitors of activin receptor-like kinase
ZA201906822B (en) Indole ahr inhibitors and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2022004304A (es) Agentes inductores de apoptosis.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3706749A4 (en) MACROCYCLIC COMPOUNDS AS TRK CINEMA INHIBITORS AND THEIR USES
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
PH12019501639A1 (en) Jaki selective inhibitors
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
MY194873A (en) Fused Bicyclic Heteroaryl Derivatives Having Activity as Phd Inhibitors
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FOCHON BIOSCIENCES, LTD.